research EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management
The document provides advice on how to recognize and treat skin-related side effects of cancer drugs known as EGFR inhibitors.
Search
for
Sort by
Research
30-60 / 1000+ results 
research Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
New chemotherapy drugs cause skin side effects, but treatments like minocycline and tetracycline can help reduce them.
research Dermatologic Reactions to Targeted Therapy
Targeted cancer therapies can cause skin side effects, which should be treated early to help patients' quality of life and treatment adherence.
research Exuberant tufted folliculitis
Tufted folliculitis is common in patients with folliculitis decalvans.
research A Case of Cicatricial Alopecia Associated with Erlotinib
Erlotinib can cause hair loss as a side effect.
research Diffuse plate-like sheets of desquamation
The rash resolved after stopping ponatinib.
research Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies
research Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas
Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.
research Gefitinib: an adverse effects profile
Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.
research BAYONET trial: staged combination with encorafenib, binimetinib, plus cetuximab following encorafenib plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer
The combination treatment showed a higher response rate but no significant survival benefits.
research Lysocellin, a metabolite of the novel drug ‘alopestatin’, induces G1 arrest and prevents cytotoxicity induced by etoposide
Lysocellin helps stop cell damage from etoposide and may prevent hair loss.
research Erlotinib-Induced Skin Inflammation Is IL-1 Mediated in KC-Tie2 Mice and Human Skin Organ Culture
Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.
research Folliculitis decalvans associated with erlotinib
Erlotinib can cause hair loss and scalp issues, which improve after stopping the drug.
research Synergistic effect of sorafenib with Platycladus orientalis (L) leaf extract on cervical cancer
Sorafenib and Platycladus orientalis leaf extract together effectively suppress cervical cancer cell growth.
research Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
research Impact of Combined Baricitinib and FTI Treatment on Adipogenesis in Hutchinson–Gilford Progeria Syndrome and Other Lipodystrophic Laminopathies
Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.
research Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.
research Linc-PINT downregulation of TGF-β signaling pathway in heart arrhythmia: an in silico analysis
Monitoring TGF-β and linc-PINT expression may help identify and treat high-risk heart arrhythmia patients.
research Upadacitinib: A New Weapon for the Treatment of Twenty-Nail Dystrophy
Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.
research Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research Anticancer drugs in surface waters
Anticancer drugs are increasingly found in surface waters, and their long-term environmental effects are not well understood, requiring better testing methods.
research Cepharanthine: An update of its mode of action, pharmacological properties and medical applications
Cepharanthine is a well-tolerated drug with multiple medical uses, including anti-inflammatory and anti-cancer properties.
research Folliculitis decalvans: a multicentre review of 82 patients
Early onset and pustules indicate severe hair follicle inflammation, and while antibiotics help, the condition often worsens after treatment stops.
research Drugs and Hair Loss
Some medications can cause hair loss, but stopping the drug usually leads to recovery within 3 months.
research Hair disorders in patients with cancer
Cancer treatments often cause hair disorders, significantly affecting patients' quality of life, and better management methods are needed.
research Drug-induced acne
Some medications can cause acne, and stopping these drugs is the main treatment.
research Alopecia With Endocrine Therapies in Patients With Cancer
Endocrine therapies for cancer significantly increase the risk of hair loss.
research Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications
Drug repurposing is a cost-effective way to find new uses for existing drugs, speeding up treatment development.
research Redefining hormone resistance in prostate cancer
The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.
research Pathogenesis and treatment options for chemotherapy‐induced alopecia: a systematic review
Scalp cooling is the most effective FDA-approved method to prevent chemotherapy-induced hair loss, but more research is needed for other treatments.